Michele Diana1, Luigi Schiraldi2, Yu-Yin Liu3, Riccardo Memeo4, Didier Mutter5, Patrick Pessaux4, Jacques Marescaux1. 1. IRCAD, Research Institute Against Cancer of the Digestive System, Strasbourg, France;; IHU-Strasbourg, Institute for Image-Guided Surgery, Strasbourg, France; 2. IRCAD, Research Institute Against Cancer of the Digestive System, Strasbourg, France ; 3. IRCAD, Research Institute Against Cancer of the Digestive System, Strasbourg, France;; Department of General Surgery, Chang Gung Memorial Hospital, Linkou, Chang Gung University, Taoyuan, Taiwan; 4. IHU-Strasbourg, Institute for Image-Guided Surgery, Strasbourg, France;; Department of Digestive Surgery, University Hospital of Strasbourg, France. 5. IRCAD, Research Institute Against Cancer of the Digestive System, Strasbourg, France;; Department of Digestive Surgery, University Hospital of Strasbourg, France.
Abstract
BACKGROUND: High intensity focused ultrasound (HIFU) is emerging as a valid minimally-invasive image-guided treatment of malignancies. We aimed to review to current state of the art of HIFU therapy applied to the digestive system and discuss some promising avenues of the technology. METHODS: Pertinent studies were identified through PubMed and Embase search engines using the following keywords, combined in different ways: HIFU, esophagus, stomach, liver, pancreas, gallbladder, colon, rectum, and cancer. Experimental proof of the concept of endoluminal HIFU mucosa/submucosa ablation using a custom-made transducer has been obtained in vivo in the porcine model. RESULTS: Forty-four studies reported on the clinical use of HIFU to treat liver lesions, while 19 series were found on HIFU treatment of pancreatic cancers and four studies included patients suffering from both liver and pancreatic cancers, reporting on a total of 1,682 and 823 cases for liver and pancreas, respectively. Only very limited comparative prospective studies have been reported. CONCLUSIONS: Digestive system clinical applications of HIFU are limited to pancreatic and liver cancer. It is safe and well tolerated. The exact place in the hepatocellular carcinoma (HCC) management algorithm remains to be defined. HIFU seems to add clear survival advantages over trans arterial chemo embolization (TACE) alone and similar results when compared to radio frequency (RF). For pancreatic cancer, HIFU achieves consistent cancer-related pain relief. Further research is warranted to improve targeting accuracy and efficacy monitoring. Furthermore, additional work is required to transfer this technology on appealing treatments such as endoscopic HIFU-based therapies.
BACKGROUND: High intensity focused ultrasound (HIFU) is emerging as a valid minimally-invasive image-guided treatment of malignancies. We aimed to review to current state of the art of HIFU therapy applied to the digestive system and discuss some promising avenues of the technology. METHODS: Pertinent studies were identified through PubMed and Embase search engines using the following keywords, combined in different ways: HIFU, esophagus, stomach, liver, pancreas, gallbladder, colon, rectum, and cancer. Experimental proof of the concept of endoluminal HIFU mucosa/submucosa ablation using a custom-made transducer has been obtained in vivo in the porcine model. RESULTS: Forty-four studies reported on the clinical use of HIFU to treat liver lesions, while 19 series were found on HIFU treatment of pancreatic cancers and four studies included patients suffering from both liver and pancreatic cancers, reporting on a total of 1,682 and 823 cases for liver and pancreas, respectively. Only very limited comparative prospective studies have been reported. CONCLUSIONS: Digestive system clinical applications of HIFU are limited to pancreatic and liver cancer. It is safe and well tolerated. The exact place in the hepatocellular carcinoma (HCC) management algorithm remains to be defined. HIFU seems to add clear survival advantages over trans arterial chemo embolization (TACE) alone and similar results when compared to radio frequency (RF). For pancreatic cancer, HIFU achieves consistent cancer-related pain relief. Further research is warranted to improve targeting accuracy and efficacy monitoring. Furthermore, additional work is required to transfer this technology on appealing treatments such as endoscopic HIFU-based therapies.
Entities:
Keywords:
High intensity focused ultrasound (HIFU); endoluminal applications of HIFU; liver cancer; miniature HIFU delivery system; mucosa and submucosal ablations using HIFU; pancreatic cancer
Authors: T Leslie; R Ritchie; R Illing; G Ter Haar; R Phillips; M Middleton; Bm Bch; F Wu; D Cranston Journal: Br J Radiol Date: 2012-06-14 Impact factor: 3.039
Authors: Tan To Cheung; Ferdinand S K Chu; Caroline R Jenkins; Dickson S F Tsang; Kenneth S H Chok; Albert C Y Chan; Thomas C C Yau; See Ching Chan; Ronnie T P Poon; Chung Mau Lo; Sheung Tat Fan Journal: World J Surg Date: 2012-10 Impact factor: 3.352
Authors: Tan To Cheung; Ronnie Tung Ping Poon; Thomas Yau; Dickson Sing Fung Tsang; Chung Mau Lo; Sheung Tat Fan Journal: Int J Colorectal Dis Date: 2011-08-13 Impact factor: 2.571
Authors: Giovanni Mauri; Luca Nicosia; Zhen Xu; Salvatore Di Pietro; Lorenzo Monfardini; Guido Bonomo; Gianluca Maria Varano; Francesco Prada; Paolo Della Vigna; Franco Orsi Journal: Br J Radiol Date: 2018-01-17 Impact factor: 3.039
Authors: Fujie Jiang; Lu Wang; Yu Tang; Yaotai Wang; Ningshan Li; Disen Wang; Zhong Zhang; Li Lin; Yan Du; Xia Ou; Jianzhong Zou Journal: Int J Nanomedicine Date: 2022-07-04
Authors: Bela Kis; Ghassan El-Haddad; Rahul A Sheth; Nainesh S Parikh; Suvranu Ganguli; Paul B Shyn; Junsung Choi; Karen T Brown Journal: Cancer Control Date: 2017 Jul-Sep Impact factor: 3.302
Authors: Tatiana D Khokhlova; George R Schade; Yak-Nam Wang; Sergey V Buravkov; Valeriy P Chernikov; Julianna C Simon; Frank Starr; Adam D Maxwell; Michael R Bailey; Wayne Kreider; Vera A Khokhlova Journal: Sci Rep Date: 2019-12-27 Impact factor: 4.379